Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonrotoclax vs Venetoclax Combinations in R/R CLL/SLL
NCT06943872Phase 3Recruiting
- Sponsor
- BeOne Medicines
- Start
- Jun 2025
- Primary completion
- Sep 2029
- Modality
- Orthosteric Ligands
- Countries
- 21
01
Overview
Phase 3, randomised, open-label trial of sonrotoclax in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (4 arms), sponsored by BeOne Medicines. Primary endpoint: Progression-Free Survival at 51 months. Started Jun 2025; status: recruiting.
02
Drugs
sonrotoclax
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT06943872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06943872.